Medical Monitoring
Physician medical monitoring for biopharma clinical trials: eligibility and safety decisions, adverse event assessment, and safety governance.
More on clinical trial medical monitoringServices
Clinical development consulting: development strategy through trial execution
Medical services start at trial concept, indication selection, population selection, trial design, regulatory document development, study feasibility, interrogation of enrollment projections and site selection, and oversight throughout the conduct of the trial through the CSR.
Covered in Depth
Three areas described on their own pages
Therapeutic Area Expertise
The physician network's depth across oncology, immunology, inflammation, and critical care programs.
More on therapeutic area expertiseSite Feasibility & Enrollment
Clinical trial site feasibility, site selection, enrollment projections, and investigator engagement from startup through conduct.
More on clinical trial site feasibility and enrollmentAreas of Engagement
Areas of Work
01
Fractional Chief Medical Officer & Clinical Development Leadership
Senior medical leadership for a program or a company that needs it without building and carrying a permanent senior clinical organization. The role can sit at the head of a development program, alongside an existing clinical team, or beside a founder or chief executive who needs a physician accountable for clinical decisions. Responsibilities are defined explicitly at the outset: what is decided, what is reviewed, and what is escalated. Medical accountability is therefore clear to the team, the board, and the CRO.
02
Clinical Development Strategy
Indication selection, definition of the development pathway, first-in-human through proof-of-concept strategy, and the clinical development plan that connects them. Work at this level addresses which population to study first, what a study has to show before the next one is justified, how the sequence of trials supports a registrational path, and where the assumptions in a plan are most likely to fail. The output is a plan a team can execute and a board can examine.
03
Protocol Design & Optimization
Protocol development and critical review, eligibility criteria, endpoint selection, and feasibility assessment. Protocols are examined as they will actually be run: whether the eligibility criteria describe patients that sites can find, whether the assessment schedule is deliverable in ordinary clinical practice, whether the endpoints answer the development question, and where the protocol will generate avoidable deviations, screen failures, or amendments.
04
Medical Monitoring & Safety Oversight
Ongoing medical review across a running study: adverse event and serious adverse event assessment, eligibility determinations, protocol deviation decisions, investigator queries, and review of laboratory and clinical data. This is physician work performed at study pace, with judgment applied to the individual patient in front of the site while keeping the emerging safety profile of the program in view.
More on clinical trial medical monitoring05
Regulatory & FDA Strategy
Regulatory pathway definition, IND strategy, and preparation for and participation in meetings with FDA. Supporting work includes briefing books, investigator brochures, clinical study reports, and the clinical positions that have to be defensible in a meeting rather than only in a slide. Preparation covers the questions likely to be asked, the data that answers them, and the positions the sponsor should and should not take.
06
Safety Governance
Strategy for data safety monitoring boards and safety monitoring committees, charter development, and participation. Governance is designed so that the committee has the data it needs, the decision rules are specified before they are tested, and the sponsor's separation from unblinded review is maintained. Where a program has already begun, existing charters and practices can be reviewed against what the study is actually generating.
07
CRO & Vendor Oversight
Selection, direction, and performance management of contract research organizations and clinical vendors. Work includes evaluating candidate providers for therapeutic relevance rather than capability statements, defining what the sponsor retains, setting the oversight cadence and the metrics that matter, and intervening when performance drifts. A CRO managed by a physician who has run the same work behaves differently from one managed by contract alone.
08
Investigator, Site & Enrollment Strategy
Site selection, investigator and key opinion leader engagement, enrollment acceleration, and troubleshooting of underperforming sites. Enrollment problems are diagnosed rather than escalated: whether the difficulty lies in the protocol, the referral pathway, the site's patient population, competing studies, or the study's standing with investigators, and what can realistically be changed.
More on clinical trial site feasibility and enrollment09
Executive & Board Level Advisory
Clinical development counsel to executives, boards, and investors, including evaluation of development programs. Work at this level addresses whether a plan is credible, what a study can and cannot support, where the clinical and regulatory risk actually sits, and what the next decision point requires, all described in terms a technical audience can test.
How Engagements Work
Scope follows what the program requires
Scope and duration are defined by the program, not by a template. An engagement may be a defined piece of work, such as a protocol review, preparation for a regulatory meeting, a development plan, or a diagnosis of an enrollment problem. It may equally be sustained senior leadership across a development program over time.
Engagements can be strategic, hands on, or both. Some programs need a physician to set direction and then step back; others need someone accountable for the clinical work week to week, in the protocol, in the safety data, and with the CRO.
DF Clinical will also say plainly when this is not the right kind of help. If a program needs a capability outside this scope, or is at a stage where senior clinical leadership would not change the outcome, that is a more useful answer than an engagement.
Strategy and Execution
Continuity from planning to execution
The services above are deliberately continuous: the same physician who defines the pathway can write and defend the protocol, make the eligibility and safety calls while the study runs, direct the CRO, and stand behind the data when it is interpreted. Programs lose time in the gap between those two levels, and closing it is the point of the work.
Describe the program and where it currently stands and we will tell you plainly whether this is the right kind of help.
Tell us where the program stands.
A short first conversation is usually enough to establish whether senior clinical leadership is what the program needs. DF Clinical is based in Cary, North Carolina and works with sponsors and CROs across the globe.